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SUMMARY
Introduction Acute lower limb ischemia results from thrombosis or embolization of diseased native 
artery or previously implanted bypass graft. When this occurs, several options are available to restore 
blood flow: catheter-directed thrombolysis, mechanical thrombectomy or open surgery. Fundamental 
reasons to apply percutaneous interventions are avoiding open procedures in high risk patients, and 
avoiding difficult dissection through scar tissue.
Case Outline A 67-year-old male was admitted at our Institution for critical limb ischemia. After per-
formed angiography the diagnosis of occluded femoropopliteal graft was established. Occlusion was 
resolved by catheter-directed thrombolysis with plasmin. Culprit lesions were treated by angioplasty.
Conclusion Our patient underwent a successful thrombolysis of occluded femoropopliteal graft with 
locally-delivered human plasmin.
Keywords: percutaneous intervention; catheter-directed thrombolysis; human plasmin; femoropopliteal 
bypass
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INTRODUCTION
Peripheral artery occlusive disease is common 
and potentially serious problem. It is usually 
caused by atherosclerotic plaques which cause 
reduction of blood flow in lower extremities. It 
affects approximately 20% of adults older than 
55 years, and increases significantly with age 
rising to 25%, among those over 80 years of 
age [1, 2].
Acute lower limb ischemia results from 
thrombosis or embolization of diseased native 
artery or previously implanted bypass graft. 
When such event occurs several options are 
available to restore blood flow: catheter-direct-
ed thrombolysis, mechanical thrombectomy or 
open surgery which is associated with higher 
morbidity and mortality compared with the 
first two methods of revascularization [3, 4].
Fundamental reasons to apply percutaneous 
interventions thus are avoiding open surgical 
procedures in high risk patients, and avoiding 
difficult dissection through scar tissue.
CASE REPORT
A 67-year-old male was admitted to our hos-
pital due to critical limb ischemia. The patient 
was experiencing rest pain in the right foot with 
a sudden onset three days earlier. Past medical 
history included hypertension, dyslipidemia 
and heavy smoking. Three years prior to this 
hospitalization the patient underwent translu-
minal angioplasty and stenting of left iliac ar-
tery and redo right femoropopliteal above knee 
bypass with a Dacron graft. Clinical examina-
tion revealed absent pulses distal from the right 
groin. Ankle-brachial index on admission on 
the right leg was 0. CT angiography (Figure 1) 
and color duplex scan confirmed occlusion of 
femoropopliteal bypass, and significant steno-
sis of right iliac artery. The popliteal artery was 
patent as were all three crural vessels.
After preparation, the patient was trans-
ferred to the Radiology Department. After 
puncturing contralateral common femoral ar-
tery, a guidewire was inserted and a six French 
sheet was placed. Heparin (10000 IU) was 
given intravenously. The stenotic right iliac 
artery was resolved by balloon angioplasty. 
A guidewire was advanced into the occluded 
femoropopliteal graft. A multi–side-hole infu-
sion catheter ( Angiodynamics Unifuse cath-
eter, USA) was positioned into the thrombosed 
graft. Plasmin (Talecris Biotherapeutics, USA) 
infusion was started initially with pulse spray 
(1 ml per min, for 30 ml), for the initiation of 
thrombolysis, and continued for four and half 
hours of 45 ml of solution. Total dose of 150 mg 
(75 ml) of plasmin was administered. Follow-
up angiography was performed after 2 hours 
and at the end of the treatment after 5 hours. 
Final angiography (Figure 2) revealed resolu-
tion of all intraluminal filling defects, and criti-
cal stenosis at the level of proximal and distal 
anastomosis of femoropopliteal bypass.
Former was resolved with stenting and latter 
by balloon angioplasty. There was no evidence 
of distal embolization. Double antiplatelet ther-
apy, with aspirin and clopidogrel, was contin-
ued after intervention.
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Seven days later the patient was discharged with a pat-
ent graft and ankle-brachial index 1.0. One year follow-
up showed full patency of femoropopliteal graft on CT 
angiography with patient leading normal life (Figure 3).
DISCUSSION
In past, several clinical studies have been conducted com-
paring the effects of locally delivered plasminogen activa-
tors (PA) with open surgery in the treatment of acute lower 
limb ischemia [5-8].
The Rochester trial [5] compared catheter-directed 
urokinase infusion with surgery for acute limb ischemia. 
During one year follow-up no difference was found in limb 
salvage between groups and mortality was significantly 
reduced with the urokinase group of patients. Bleeding 
complications were increased in the urokinase group com-
pared to surgery.
The STILE trial (Surgery versus Thrombolysis for 
Ischemia of the Lower Extremity) [6] randomized pa-
tients to surgery or catheter-directed thrombolysis with 
Figure 1. CT angiography before thrombolysis: a) anterior view on CT angiography – arrows showing stent in left common iliac artery; stenosis 
of right iliac artery; occluded femoropopliteal graft and heavily calcified and occluded native right superficial femoral artery; b) posterior view 
on CT angiography – arrow showing occluded femoropopliteal graft and heavily calcified and occluded native right superficial femoral artery.
Figure 2. Arrow showing patent femoropopliteal graft after throm-
bolysis
Figure 3. CT angiography after thrombolysis: a) anterior view on CT angiography – arrow showing stent in proximal anastomosis of patent 
femoropopliteal graft; b) posterior view on CT angiography – arrow showing patent femoropopliteal graft.
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urokinase or recombinant tissue plasminogen activator, 
but it differed in that patients had acute (<14) and chronic 
(>14) limb ischemia. Intracranial hemorrhage occurred 
in 1.6% of patients, which is similar to the rate recorded 
in the TOPAS trial. A large benefit (fewer amputations, 
increase in amputation-free survival) was achieved for 
our patients with acute ischemia who were randomized to 
thrombolysis. However, the patients with chronic ischemia 
who were randomized to surgery experienced fewer am-
putations and improved amputation-free survival. These 
results were maintained at 1-year follow-up.
The TOPAS (Thrombolysis or Peripheral Arterial 
Surgery) [7, 8] trial randomized patients to recombinant 
urokinase or surgery, but found no difference in amputa-
tion rate (15% vs. 13%) or in amputation-free survival at 
six months and one year respectively (20% vs. 17%). Bleed-
ing complications, however, were significantly increased 
in patients randomized to urokinase therapy.
Results from randomized clinical trials suggest that 
thrombolytic therapy is superior to surgery for treatment 
of acute (less than 14 days) occlusions regarding bypass 
graft occlusions and long occlusions without adequate 
run-off vessel suitable for surgical bypass. However, open 
surgery should be recommended for subacute or chronic 
occlusions and in native arteries occlusions [9].
Currently held opinions on the role of catheter-based 
thrombolysis therapy in the patients with acute leg 
ischemia, can be considered as complementary with sur-
gical or percutaneous revascularization with an acceptably 
low complication rate [10, 11].
The goal of catheter-directed intra-arterial thromboly-
sis is to eliminate occluding thrombus and restore native 
artery or bypass graft patency. In that way the underly-
ing lesion is revealed and could be treated by angioplasty 
thus avoiding open surgery and reducing morbidity and 
mortality [12].
It has been shown that systemic infusion of plasminogen 
activators is ineffective when compared to catheter-directed 
intra-thrombus infusion [13, 14]. Catheter-directed throm-
bolysis provides maximal delivery of agent to a thrombus, 
thus improving the degree of thrombolysis [15, 16].
The fibrinolytic system is based upon conversion of an 
inactive pro-enzyme plasminogen, to active form plasmin 
by plasmin activators. Physiologic dissolution of thrombus 
occurs by plasmin action on fibrin [17]. Free plasmin is 
inactivated rapidly by plasma alpha-2-antiplasmin, a natu-
rally occurring protease inhibitor. This results in both a 
decrease in plasmin production and a decrease in the dis-
solution of fibrin clots [18]. But when bound to a throm-
bus, plasmin is protected from inhibition [19], thereby 
allowing an effective thrombolysis.
The limitations of plasminogen activators (PA) usage 
is that they are released systemically even when delivered 
locally by catheter. This increases a bleeding risk because 
fibrinolysis is activated at sites of remote vascular injury or 
malformation [20]. The most severe hemorrhagic compli-
cation of catheter-delivered PA is intracranial hemorrhage, 
occurring in 1-2.8% of patients [21, 22, 23] and higher, 
correlated with poor hypertensive control [24].
Different studies have suggested that the use of uroki-
nase may be associated with a lower incidence of hem-
orrhagic complications compared to recombinant tissue 
plasminogen activator (rtPA) [9].
However, in 2010 Cochrane systematic review stated 
that the incidence of bleeding complications was not sta-
tistically significantly greater with rtPA than with other 
regimes [20].
The other drawback of PA use is that they need plas-
minogen in order to express action. Since thrombus-asso-
ciated plasminogen may be present in limited supply [25], 
it can result in suboptimal lysis of retracted thrombi and 
incomplete reperfusion of occluded vessels.
On the contrary, human plasmin biochemisty is favora-
ble because it is rapidly and irreversibly inhibited by alpha-
2-antiplasmin and it is a direct-acting fibrinolytic [25, 26] 
not requiring plasminogen to achieve fibrinolysis. The 
physiologic relevance of these attributes of plasmin is sup-
ported by animal studies [26]. Experimental data indicate 
that we should recognize plasmin as viable, even preferable 
thrombolytic agent. The most recent pre-clinical studies 
and reports confirm that plasmin has marked hemostatic 
safety advantage over t-PA, and superior-thrombolytic ef-
ficiency, when delivered by catheter to occluded arteries 
[27-31].
After more than 50 years, the field has come full circle, 
and plasmin as the thrombolytic agent and catheter use 
for local delivery of agent may represent a step forward in 
thrombolytic therapy compared to PA [32].
Marder [33] proposed that locally-delivered plasmin 
could also have a significant role in the treatment of deep 
vein thrombosis due to its safety and efficacy compared 
to PA.
First-in-human experiences with locally administered 
plasmin were gained by Shlansky-Goldberg et al. [27, 34] 
in the study where thrombosed synthetic hemodialysis 
access grafts were treated for occlusion. The overall con-
clusion of this Phase I study was that human plasmin was 
safe and well tolerated in the hemodialysis graft occlusion 
subject population, and showed a dose response throm-
bolytic trend.
Our patient was a part of Phase I PRIORITY (Plas-
min Revascularization for the Ischemic Lower Extremity) 
study - the first human dose-escalation trial of plasmin in 
patients with acute limb ischemia. Although successful in 
our case, we should wait end of the study to obtain more 
valid conclusions.
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КРАТАК САДРЖАЈ
Увод Ис хе ми ја до њих екс тре ми те та је по сле ди ца тром бо зе 
или ем бо ли за ци је обо ле ле на тив не ар те ри је или им план ти-
ра ног граф та. По сто ји не ко ли ко на чи на ле че ња ис хе ми је: 
тром бо ли за ка те те ром, ме ха нич ка тром бек то ми ја и хи рур-
шко ле че ње. Основ ни раз ло зи за при ме ну пер ку та них ин-
тер вен ци ја је сте из бе га ва ње кла сич ног хи рур шког ле че ња 
код бо ле сни ка с ви со ким ри зи ком, као и из бе га ва ње пре-
па ри са ња крв ног су да у ожиљ ку.
При каз бо ле сни ка Му шка рац стар 67 го ди на при мљен је 
у бол ни цу због кри тич не ис хе ми је до њих екс тре ми те та. По 
учи ње ној ан ги о гра фи ји ди јаг но сти ко ва на је тром бо за фе мо-
ро по пли те ал ног граф та. Оклу зи ја је ре ше на при ме ном пла-
зми на уз упо тре бу ин тра ар те риј ског ка те те ра. Сте но зе ко је 
су от кри ве не по сле тром бо ли зе ле че не су ан ги о пла сти ком.
За кљу чак Тром бо ли зом уз при ме ну пла зми на и ин тра ар-
те риј ског ка те те ра успе шно је из ле че на оклу зи ја фе мо ро-
по пли те ал ног граф та.
Кључ не ре чи: пер ку та не ин тер вен ци је; тром бо ли за ка те те-
ром; ху ма ни пла змин; фе мо ро по пли те ал ни графт
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